INTELLIA THERAPEUTICS, INC.

(NTLA)
  Report
Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
60.41 USD   -4.85%
08/05SECTOR UPDATE : Health Care Stocks Drifting Lower Near Friday Close
MT
08/05SECTOR UPDATE : Health Care
MT
08/05Goldman Sachs Adjusts Price Target for Intellia Therapeutics to $159 From $180, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Health Care

06/24/2022 | 08:56am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
INTELLIA THERAPEUTICS, INC. -4.85% 60.41 Delayed Quote.-48.91%
NASDAQ COMPOSITE -1.19% 12493.93 Real-time Quote.-19.18%
REGENERON PHARMACEUTICALS, INC. -1.34% 622.15 Delayed Quote.-1.48%
All news about INTELLIA THERAPEUTICS, INC.
08/05SECTOR UPDATE : Health Care Stocks Drifting Lower Near Friday Close
MT
08/05SECTOR UPDATE : Health Care
MT
08/05Goldman Sachs Adjusts Price Target for Intellia Therapeutics to $159 From $180, Maintai..
MT
08/05Credit Suisse Raises Intellia Therapeutics' Price Target to $101 from $98, Keeps Outper..
MT
08/05Piper Sandler Adjusts Price Target on Intellia Therapeutics to $163 From $171, Reiterat..
MT
08/05Wedbush Cuts Price Target on Intellia Therapeutics to $58 From $68, After Q2 Report, Al..
MT
08/05Chardan Research Cuts Price Target on Intellia Therapeutics to $146 From $172, Citing Q..
MT
08/04INTELLIA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
08/04Intellia Therapeutics Reports Wider Q2 Net Loss; Shares Slip
MT
08/04TRANSCRIPT : Intellia Therapeutics, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
More news
Analyst Recommendations on INTELLIA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 49,8 M - -
Net income 2022 -443 M - -
Net cash 2022 625 M - -
P/E ratio 2022 -10,3x
Yield 2022 -
Capitalization 4 592 M 4 592 M -
EV / Sales 2022 79,7x
EV / Sales 2023 85,3x
Nbr of Employees 485
Free-Float 90,3%
Chart INTELLIA THERAPEUTICS, INC.
Duration : Period :
Intellia Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTELLIA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 60,41 $
Average target price 123,21 $
Spread / Average Target 104%
EPS Revisions
Managers and Directors
John M. Leonard President, Chief Executive Officer & Director
Glenn Goddard Treasurer, Chief Financial & Accounting Officer
Frank A. G. M. Verwiel Chairman
Laura Sepp-Lorenzino Chief Scientific Officer & Executive VP
Eliana Clark Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INTELLIA THERAPEUTICS, INC.-48.91%4 592
MODERNA, INC.-32.62%66 950
LONZA GROUP AG-26.76%43 416
IQVIA HOLDINGS INC.-17.56%43 382
SEAGEN INC.13.58%32 387
ALNYLAM PHARMACEUTICALS, INC.31.72%26 810